Eliana Merle
Stock Analyst at UBS
(2.92)
# 1,256
Out of 4,667 analysts
66
Total ratings
30%
Success rate
5.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $4.52 | +165.49% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.74 | +9.49% | 1 | Nov 12, 2024 | |
| ALT Altimmune | Initiates: Buy | $26 | $8.05 | +222.98% | 1 | Nov 12, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $74 | $44.05 | +67.99% | 2 | Nov 4, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $411 → $441 | $317.09 | +39.08% | 3 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $104 → $106 | $62.56 | +69.44% | 1 | Oct 30, 2024 | |
| ANAB AnaptysBio | Maintains: Neutral | $23 → $33 | $20.31 | +62.48% | 4 | Oct 30, 2024 | |
| MRNA Moderna | Maintains: Buy | $140 → $108 | $36.94 | +192.37% | 4 | Oct 24, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $97 → $131 | $102.14 | +28.26% | 6 | Sep 18, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $10 → $2 | $1.07 | +86.92% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $27.49 | +201.93% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $248.79 | +15.76% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $3.13 | +59.74% | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $23.04 | +103.99% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $5.79 | -13.64% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $5.60 | +221.43% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $42 | $30.64 | +37.10% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $57.07 | -29.91% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $25 | $7.98 | +213.28% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $5.70 | +636.84% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $2.49 | +622.89% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.70 | +1,048.60% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $8.36 | +163.16% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $9.63 | +388.06% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.59 | +66.84% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $22.69 | +442.09% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $25.64 | +422.62% | 3 | Aug 19, 2020 |
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $4.52
Upside: +165.49%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.74
Upside: +9.49%
Altimmune
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $8.05
Upside: +222.98%
Kymera Therapeutics
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $44.05
Upside: +67.99%
Madrigal Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $317.09
Upside: +39.08%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Buy
Price Target: $104 → $106
Current: $62.56
Upside: +69.44%
AnaptysBio
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $20.31
Upside: +62.48%
Moderna
Oct 24, 2024
Maintains: Buy
Price Target: $140 → $108
Current: $36.94
Upside: +192.37%
BioNTech SE
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $102.14
Upside: +28.26%
RAPT Therapeutics
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $1.07
Upside: +86.92%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $27.49
Upside: +201.93%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $248.79
Upside: +15.76%
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $3.13
Upside: +59.74%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $23.04
Upside: +103.99%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $5.79
Upside: -13.64%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $5.60
Upside: +221.43%
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $30.64
Upside: +37.10%
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $57.07
Upside: -29.91%
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $7.98
Upside: +213.28%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $5.70
Upside: +636.84%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.49
Upside: +622.89%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.70
Upside: +1,048.60%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $8.36
Upside: +163.16%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $9.63
Upside: +388.06%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.59
Upside: +66.84%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $22.69
Upside: +442.09%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $25.64
Upside: +422.62%